Faricimab outperforms anti-VEGF Drugs in DME and AMD Treatment by improving central subfoveal thickness
Written By : Aditi
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-01-05 17:15 GMT | Update On 2024-01-05 17:15 GMT
Advertisement
In the industrialized world, Neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) cause blindness. Faricimab, launched in the US in January 2022, treats diabetic macular edema and wet age-related macular degeneration. Based on evidence from Systematic reviews, anti-VEGF agents' are advantageous in AMD and DME compared to other therapies.
In a study published in the Medicine (Baltimore), researchers found Faricimab to be significantly advantageous in improving central subfoveal thickness (CST) and reducing injection numbers for DME and AMD patients compared to other anti-VEGF drugs, with high-strength and moderate-strength evidence, respectively.
The review evaluated and compared Faricimab's safety and efficacy against VEGF therapy for neovascular AMD and DME. They conducted a literature search of electronic databases for RCTs of Faricimab for AMD and DME from 2013 to 2023 and used weighted mean differences and risk ratios to combine the studies.
Study results include the following points:
· 4 RCTs with 1678 AMD patients and 3 RCTs with 20 DME patients were included.
· In AMD patients, a significant difference was found in the number of injections between Faricimab and other anti-VEGF therapy with MD −2.42.
· No significant differences were found for change in BVCA, CST , gaining 15 or more letters, or adverse events.
· In DME patients, a significant difference was observed for CST (MD = −22.41) and the number of injections (MD = −0.93).
· No significant differences were found for BVCA change, gaining 15 or more letters, or for adverse events.
The study established a reference for the clinical application of faricimab, which blocks VEGF through Ang-2 and VEGF-A to promote vascular stability. Faricimab's effectiveness in improving anatomical outcomes and extending durability with dosing every 16 weeks addresses the need for durable therapies optimizing real-world outcomes.
Reference:
Li G, Zhu N, Ji A. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2023 Dec 15;102(50):e36370.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.